{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:16:06Z","timestamp":1772774166456,"version":"3.50.1"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Brucellosis is a zoonotic disease that is prevalent in livestock animals.\nThe bacteria reside inside the macrophage cells of the host. The WHO has endorseda combination\ntreatment therapy for brucellosis against the conventional monotherapy to avoid relapse and resistance.\nTherefore, we developed nanoparticles incorporating doxycycline and rifampicin in combination.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>The aim of the study is to develop polymeric nanoparticles incorporating doxycycline as well\nas rifampicin and investigate the antibacterial activity of nanoparticles in U937 human macrophage\ncells infected with B. abortus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Polymeric nanoparticles were developed by the emulsion-solvent diffusion method, and\ncharacterization was performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The nanoparticles with high entrapment efficiency of both the drugs were developed successfully.\nScanning electron microscopy revealed a spherical morphology with a size ranging\n~450nm, which can be easily engulfed by the macrophages. Zeta potential confirmed the colloidal\nstability. Differential scanning calorimetry and X-ray diffraction suggested amorphization of doxycycline\nand rifampicin in nanoparticles. Fourier transfer infrared spectroscopy could not confirm\nthe interaction of drugs with AOT. In vitro haemolysis study confirmed the safety of nanoparticles\n(&lt;10%) for IV administration. Further, nanoparticles revealed the sustained release of both drugs,\nwhich followed diffusion kinetics. Nanoparticles were found stable for 6 months as per WHO\nguidelines. The internalization study revealed nanoparticles could be easily uptaken by U-937 human\nmacrophage cells. The efficacy study demonstrated significantly high antibacterial activity of\nnanoparticles as compared to free drug solution in U937 human macrophages cells infected with\nBrucella abortus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It can be concluded that the developed nanoparticles entrapping doxycycline and rifampicin\ncombination can be considered as a promising delivery system for enhancing the antibacterial\nactivity against Brucella abortus.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201818666210609164704","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T11:27:23Z","timestamp":1624274843000},"page":"104-116","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Enhanced Antibacterial Activity of Doxycycline and Rifampicin Combination\nLoaded in Nanoparticles against Intracellular Brucella abortus"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-0002","authenticated-orcid":true,"given":"Shilpa","family":"Dawre","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy &amp; Technology Management, SVKM, NMIMS, Maharashtra\n425405, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padma V.","family":"Devarajan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Institute of Chemical Technology, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Samad","sequence":"additional","affiliation":[{"name":"Department\nof Microbiology, Bombay Veterinary College, Parel Village, Parel, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"World Health Organization 2020. Available from:"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.ajpath.2015.03.003","volume":"185","author":"de Figueiredo P.","year":"2015","unstructured":"de Figueiredo P.; Ficht T.A.; Rice-Ficht A.; Rossetti C.A.; Adams L.G.; Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions. Am J Pathol 2015,185(6),1505-1517","journal-title":"Am J Pathol"},{"key":"ref=3","first-page":"636","volume":"4","author":"Alavi S.M.","year":"2013","unstructured":"Alavi S.M.; Alavi L.; Treatment of brucellosis: a systematic review of studies in recent twenty years. Caspian J Intern Med 2013,4(2),636-641","journal-title":"Caspian J Intern Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/fmb.12.140","volume":"8","author":"Martirosyan A.","year":"2013","unstructured":"Martirosyan A.; Gorvel J-P.; Brucella evasion of adaptive immunity. Future Microbiol 2013,8(2),147-154","journal-title":"Future Microbiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0378-1135(02)00367-X","volume":"92","author":"Ficht T.A.","year":"2003","unstructured":"Ficht T.A.; Intracellular survival of Brucella: defining the link with persistence. Vet Microbiol 2003,92(3),213-223","journal-title":"Vet Microbiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5772\/61327","volume":"23","author":"Chifiriuc M.C.","year":"2016","unstructured":"Chifiriuc M.C.; Holban A.M.; Curutiu C.; Ditu L-M.; Mihaescu G.; Oprea A.E.; Antibiotic drug delivery systems for the intracellular targeting of bacterial pathogens. Smart Drug Delivery System 2016,23,245-266","journal-title":"Smart Drug Delivery System"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","volume":"10","author":"Gustafson H.H.","year":"2015","unstructured":"Gustafson H.H.; Holt-Casper D.; Grainger D.W.; Ghandehari H.; Nanoparticle uptake: The phagocyte problem. Nano Today 2015,10(4),487-510","journal-title":"Nano Today"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/21691401.2019.1593858","volume":"47","author":"Ghaderkhani J.","year":"2019","unstructured":"Ghaderkhani J.; Yousefimashouf R.; Arabestani M.; Roshanaei G.; Asl S.S.; Abbasalipourkabir R.; Improved antibacterial function of Rifampicin-loaded solid lipid nanoparticles on Brucella abortus. Artif Cells Nanomed Biotechnol 2019,47(1),1181-1193","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1128\/AAC.00378-13","volume":"57","author":"Imbuluzqueta E.","year":"2013","unstructured":"Imbuluzqueta E.; Gamazo C.; Lana H.; Campanero M.&#xC1;.; Salas D.; Gil A.G.; Elizondo E.; Ventosa N.; Veciana J.; Blanco-Prieto M.J.; Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice. Antimicrob Agents Chemother 2013,57(7),3326-3333","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13756-019-0504-8","volume":"8","author":"Hosseini S.M.","year":"2019","unstructured":"Hosseini S.M.; Abbasalipourkabir R.; Jalilian F.A.; Asl S.S.; Farmany A.; Roshanaei G.; Arabestani M.R.; Doxycycline-encapsulated solid lipid nanoparticles as promising tool against Brucella melitensis enclosed in macrophage: a pharmacodynamics study on J774A.1 cell line. Antimicrob Resist Infect Control 2019,8(1),62","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1016\/S0142-9612(01)00030-8","volume":"22","author":"Fontana G.","year":"2001","unstructured":"Fontana G.; Licciardi M.; Mansueto S.; Schillaci D.; Giammona G.; Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001,22(21),2857-2865","journal-title":"Biomaterials"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1208\/s12249-012-9758-7","volume":"13","author":"Zaki N.M.","year":"2012","unstructured":"Zaki N.M.; Hafez M.M.; Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium. AAPS PharmSciTech 2012,13(2),411-421","journal-title":"AAPS PharmSciTech"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/0975-7406.124309","volume":"6","author":"Soni M.P.","year":"2014","unstructured":"Soni M.P.; Shelkar N.; Gaikwad R.V.; Vanage G.R.; Samad A.; Devarajan P.V.; Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis. J Pharm Bioallied Sci 2014,6(1),22-30","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13346-019-00670-x","volume":"10","author":"Maithania H.V.","year":"2020","unstructured":"Maithania H.V.; Mohanty B.S.; Chaudhari P.R.; Samad A.; Devarajan P.V.; Shape mediated splenotropic delivery of buparvaquone loaded solid lipid nanoparticles. Drug Deliv Transl Res 2020,10(1),159-167","journal-title":"Drug Deliv Transl Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2334-4-18","volume":"4","author":"Karabay O.","year":"2004","unstructured":"Karabay O.; Sencan I.; Kayas D.; Sahin I.; Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]. BMC Infect Dis 2004,4,18","journal-title":"BMC Infect Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/jac\/33.3.545","volume":"33","author":"Shasha B.","year":"1994","unstructured":"Shasha B.; Lang R.; Rubinstein E.; Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis. J Antimicrob Chemother 1994,33(3),545-551","journal-title":"J Antimicrob Chemother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.ijid.2011.12.003","volume":"16","author":"Hashemi S.H.","year":"2012","unstructured":"Hashemi S.H.; Gachkar L.; Keramat F.; Mamani M.; Hajilooi M.; Janbakhsh A.; Majzoobi M.M.; Mahjub H.; Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. Int J Infect Dis 2012,16(4),e247-e251","journal-title":"Int J Infect Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-117-1-25","volume":"117","author":"Ariza J.","year":"1992","unstructured":"Ariza J.; Gudiol F.; Pallares R.; Viladrich P.F.; Rufi G.; Corredoira J.; Miravitlles M.R.; Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992,117(1),25-30","journal-title":"Ann Intern Med"},{"key":"ref=19","author":"Ranjbar M.","year":"2015","unstructured":"Ranjbar M.; Treatment of Brucellosis. Updates on Brucellosis 2015","journal-title":"Updates on Brucellosis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijpharm.2008.05.039","volume":"362","author":"Chen W.","year":"2008","unstructured":"Chen W.; Gu B.; Wang H.; Pan J.; Lu W.; Hou H.; Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm 2008,362(1-2),133-140","journal-title":"Int J Pharm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/jac\/dki372","volume":"56","author":"Brown D.F.","year":"2005","unstructured":"Brown D.F.; Edwards D.I.; Hawkey P.M.; Morrison D.; Ridgway G.L.; Towner K.J.; Wren M.W.; Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 2005,56(6),1000-1018","journal-title":"J Antimicrob Chemother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1208\/s12249-010-9382-3","volume":"11","author":"Date P.V.","year":"2010","unstructured":"Date P.V.; Samad A.; Devarajan P.V.; Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech 2010,11(1),304-313","journal-title":"AAPS PharmSciTech"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1166\/jbn.2008.320","volume":"4","author":"Patil R.R.","year":"2008","unstructured":"Patil R.R.; Gaikwad R.V.; Samad A.; Devarajan P.V.; Role of lipids in enhancing splenic uptake of polymer-lipid (LIPOMER) nanoparticles. J Biomed Nanotechnol 2008,4(3),359-366","journal-title":"J Biomed Nanotechnol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11095-008-9626-z","volume":"26","author":"Champion J.A.","year":"2009","unstructured":"Champion J.A.; Mitragotri S.; Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009,26(1),244-249","journal-title":"Pharm Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3109\/10717544.2015.1135488","volume":"23","author":"Pranatharthiharan S.","year":"2016","unstructured":"Pranatharthiharan S.; Patel M.D.; Malshe V.C.; Devarajan P.V.; Polyethylene sebacate doxorubicin nanoparticles: role of carbohydrate anchoring on in vitro and in vivo anticancer efficacy. Drug Deliv 2016,23(8),2980-2989","journal-title":"Drug Deliv"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijpharm.2004.11.010","volume":"294","author":"Pi\u00f1&#xF3;n-Segundo E.","year":"2005","unstructured":"Pi\u00f1&#xF3;n-Segundo E.; Ganem-Quintanar A.; Alonso-P\u00e9rez V.; Quintanar-Guerrero D.; Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int J Pharm 2005,294(1-2),217-232","journal-title":"Int J Pharm"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nature01451","volume":"422","author":"Conner S.D.","year":"2003","unstructured":"Conner S.D.; Schmid S.L.; Regulated portals of entry into the cell. Nature 2003,422(6927),37-44","journal-title":"Nature"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1574-6968.2009.01530.x","volume":"294","author":"Seleem M.N.","year":"2009","unstructured":"Seleem M.N.; Jain N.; Pothayee N.; Ranjan A.; Riffle J.S.; Sriranganathan N.; Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline. FEMS Microbiol Lett 2009,294(1),24-31","journal-title":"FEMS Microbiol Lett"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201818666210609164704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193997\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201818666210609164704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:16:39Z","timestamp":1668856599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193997\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201818666210609164704","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-12-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}